CLDX Profile
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to advancing therapeutic monoclonal and bispecific antibodies aimed at treating a range of diseases. The company's robust pipeline includes antibody-based therapies designed for patients with inflammatory conditions and various types of cancer. Among its prominent drug candidates are CDX-0159, currently in Phase I trials, which targets the receptor tyrosine kinase KIT to inhibit its activity. Additionally, CDX-1140, a human agonist monoclonal antibody directed at CD40 an immune response activator present on dendritic cells, macrophages, B cells, and cancer cells is in clinical development. Furthermore, CDX-527, a bispecific antibody, combines Celldex's proprietary anti-PD-L1 and CD27 antibodies to enhance anti-tumor T cell responses through CD27 costimulation while blocking the PD-L1/PD-1 pathway.
In addition to its innovative pipeline, Celldex Therapeutics has established research collaborations and license agreements to bolster its development efforts. These include partnerships with the University of Southampton for the advancement of human antibodies targeting CD27, and with Amgen Inc., securing exclusive rights to CDX-301 and CD40 ligand. The company also collaborates with Yale University to further its research initiatives. Celldex, founded in 1983 and headquartered in Hampton, New Jersey, exemplifies a commitment to pioneering biopharmaceutical innovation with a focus on improving patient outcomes through cutting-edge antibody therapies.
Celldex Therapeutics, Inc. stands at the forefront of biopharmaceutical innovation, specializing in the development of monoclonal and bispecific antibodies tailored to combat a spectrum of diseases. The company's portfolio includes promising candidates such as CDX-0159, targeting KIT receptor inhibition, and CDX-1140, an agonist antibody activating CD40 to enhance immune responses against cancer cells and other targets. Celldex's strategic collaborations, including partnerships with prestigious academic institutions like Yale University and the University of Southampton, underscore its dedication to leveraging scientific expertise and collaborative research to advance novel therapies. Headquartered in Hampton, New Jersey, Celldex continues to drive forward in the biopharmaceutical industry, aiming to transform the treatment landscape through innovative antibody-based approaches.
Investors and stakeholders in Celldex Therapeutics, Inc. benefit from its comprehensive approach to drug development and its focus on addressing critical unmet medical needs. The company's commitment to advancing therapies that harness the immune system's capabilities reflects its mission to make significant strides in the fight against cancer and inflammatory diseases. With a robust pipeline and strategic partnerships enhancing its research capabilities, Celldex remains poised to deliver impactful therapies that could potentially improve outcomes for patients worldwide.
|
